Alnylam Pharmaceuticals, Inc.
ALNY
$438.93
$3.830.88%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -292.43% | 12.82% | 39.24% | -175.51% | 93.88% |
| Total Depreciation and Amortization | -7.06% | 6.57% | -8.11% | 14.90% | -36.01% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -5.12% | 78.68% | 13.65% | -40.03% | 27.43% |
| Change in Net Operating Assets | 230.57% | -100.12% | -239.25% | 20.38% | -159.39% |
| Cash from Operations | 23.82% | -45.14% | -217.71% | -87.84% | 310.49% |
| Capital Expenditure | -78.26% | 30.86% | 40.60% | 75.47% | 49.63% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -402.89% | 324.60% | 80.56% | -511.79% | 482.26% |
| Cash from Investing | -516.56% | 268.25% | 78.01% | -181.03% | 489.53% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -38.83% | 90.90% | 17.43% | 335.54% | 168.81% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2,042.36% | -273.03% | -163.37% | -163.37% | -132.05% |
| Cash from Financing | -59.12% | 52.48% | -20.98% | 210.08% | 146.27% |
| Foreign Exchange rate Adjustments | 981.60% | 241.41% | -258.49% | 330.36% | -2,300.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -67.32% | 141.18% | 39.25% | -65.01% | 2,084.58% |